IGC PHARMA INC (IGC) Stock Earnings & Estimates
NYSEARCA:IGC - US45408X3089 - Common Stock
0.438 USD
-0.03 (-6.81%)
0.442 USD
+0 (+0.91%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 910K 127.50% | 1.345M 47.80% | 1.271M -5.50% | 1.465M 15.26% | 1.515M 3.41% | |
| EBITDA YoY % growth | -10.53M -4.99% | -8.161M 22.50% | -6.611M 18.99% | N/A | N/A | |
| EBIT YoY % growth | -11.19M -4.78% | -8.798M 21.38% | -7.229M 17.83% | -8.102M -12.08% | -10.529M -29.96% | |
| Operating Margin | -1,229.67% | -654.13% | -568.76% | -553.05% | -695.00% | |
| EPS YoY % growth | N/A | N/A | -0.08 62.20% | -0.09 -8.07% | -0.09 2.41% |
All data in USD
| Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.02 18.80% | -0.02 32.33% | -0.02 -111.39% |
| Revenue Q2Q % growth | 498.94K 21.10% | 311.08K 21.04% | 375.72K 13.85% |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.124M -19.06% | -2.237M -22.25% | -2.199M -76.61% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2026 Q2Q % growth | -0.02 33.33% | -0.02 | 0.00 | 14.05% |
| Q4 2025 Q2Q % growth | -0.01 97.50% | -0.02 | 0.01 | 41.69% |
| Q3 2025 Q2Q % growth | -0.02 | -0.03 | 0.00 | 8.50% |
| Q2 2025 Q2Q % growth | -0.02 | -0.03 | 0.01 | 23.75% |
| Q1 2025 Q2Q % growth | -0.03 | -0.03 | 0.00 | -14.37% |
| Q4 2024 Q2Q % growth | -0.40 | -0.04 | -0.36 | -890.10% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2026 Q2Q % growth | 328K 20.59% | 329.26K | -1.26K | -0.38% |
| Q4 2025 Q2Q % growth | 330K 11.86% | 308.05K | 21.95K | 7.13% |
| Q3 2025 Q2Q % growth | 257K 25.98% | 254.52K | 2.48K | 0.97% |
| Q2 2025 Q2Q % growth | 412K 42.07% | 298.455K | 113.545K | 38.04% |
| Q1 2025 Q2Q % growth | 272K -51.43% | 460.055K | -188.055K | -40.88% |
| Q4 2024 Q2Q % growth | 295K 73.53% | 194.93K | 100.07K | 51.34% |
| Q3 2024 Q2Q % growth | 204K -38.18% | % | ||
| Q2 2024 Q2Q % growth | 290K 45.00% | % | ||
| Q1 2024 Q2Q % growth | 560K 166.67% | % | ||
| Q4 2023 Q2Q % growth | 170K 41.67% | % | ||
| Q3 2023 Q2Q % growth | 330K 135.71% | % | ||
| Q2 2023 Q2Q % growth | 200K 233.33% | % | ||
| Q1 2023 Q2Q % growth | 210K 162.50% | % | ||
| Q4 2022 Q2Q % growth | 120K 50.00% | % | ||
| Q3 2022 Q2Q % growth | 140K 27.27% | % | ||
| Q2 2022 Q2Q % growth | 60K -53.85% | % | ||
| Q1 2022 Q2Q % growth | 80K -86.21% | % | ||
| Q4 2021 Q2Q % growth | 80K 166.67% | % | ||
| Q3 2021 Q2Q % growth | 110K -80.70% | % | ||
| Q2 2021 Q2Q % growth | 130K -92.86% | % | ||
| Q1 2021 Q2Q % growth | 580K -64.85% | % | ||
| Q4 2020 Q2Q % growth | 30K -98.05% | % | ||
| Q3 2020 Q2Q % growth | 570K -55.81% | % | ||
| Q2 2020 Q2Q % growth | 1.82M 124.69% | % | ||
| Q1 2020 Q2Q % growth | 1.65M 11.49% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | 0% | 0% | 0% | 0% |